BG105471A - Метод за предотвратяване или забавяне на необходимостта от катетър-основан на реваскуларизация - Google Patents

Метод за предотвратяване или забавяне на необходимостта от катетър-основан на реваскуларизация

Info

Publication number
BG105471A
BG105471A BG105471A BG10547101A BG105471A BG 105471 A BG105471 A BG 105471A BG 105471 A BG105471 A BG 105471A BG 10547101 A BG10547101 A BG 10547101A BG 105471 A BG105471 A BG 105471A
Authority
BG
Bulgaria
Prior art keywords
catheter
revivalcization
delaying
requests
preventing
Prior art date
Application number
BG105471A
Other languages
Bulgarian (bg)
English (en)
Inventor
Donald BLACK
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG105471(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG105471A publication Critical patent/BG105471A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
BG105471A 1998-09-30 2001-04-25 Метод за предотвратяване или забавяне на необходимостта от катетър-основан на реваскуларизация BG105471A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30
PCT/US1999/015385 WO2000018395A1 (en) 1998-09-30 1999-07-08 Method for preventing or delaying catheter-based revascularization

Publications (1)

Publication Number Publication Date
BG105471A true BG105471A (bg) 2001-12-31

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105471A BG105471A (bg) 1998-09-30 2001-04-25 Метод за предотвратяване или забавяне на необходимостта от катетър-основан на реваскуларизация

Country Status (34)

Country Link
US (1) US20080119561A1 (id)
EP (1) EP1117392B1 (id)
JP (1) JP2002525321A (id)
KR (1) KR20010079955A (id)
CN (1) CN1197565C (id)
AP (1) AP1708A (id)
AT (1) ATE260100T1 (id)
AU (1) AU768474B2 (id)
BG (1) BG105471A (id)
BR (1) BR9914098A (id)
CA (1) CA2343299C (id)
CZ (1) CZ20011035A3 (id)
DE (1) DE69915084T2 (id)
DK (1) DK1117392T3 (id)
EA (1) EA007427B1 (id)
EE (1) EE200100199A (id)
ES (1) ES2214872T3 (id)
HR (1) HRP20010236A2 (id)
HU (1) HUP0103648A3 (id)
ID (1) ID30255A (id)
IL (2) IL141953A0 (id)
IS (1) IS5889A (id)
NO (1) NO20011615L (id)
NZ (1) NZ510500A (id)
OA (1) OA11787A (id)
PL (1) PL346980A1 (id)
PT (1) PT1117392E (id)
SI (1) SI1117392T1 (id)
SK (1) SK4122001A3 (id)
TR (1) TR200100901T2 (id)
UA (1) UA73292C2 (id)
WO (1) WO2000018395A1 (id)
YU (1) YU23901A (id)
ZA (1) ZA200102230B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203326A3 (en) 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001078747A1 (de) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
AU2001264731A1 (en) * 2000-07-14 2002-01-30 Warner-Lambert Company Treatment of eating disorders using carboxyalkylethers
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5807388A (en) * 1994-05-25 1998-09-15 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
SE506272C2 (sv) * 1996-03-18 1997-11-24 Paul Edholm Förfarande och anordning för att bestämma bildläge och bildvinkel i en röntgenbild
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
AU3667297A (en) * 1996-07-09 1998-02-02 Merck & Co., Inc. Therapy for combined hyperlipidemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
UA73292C2 (en) 2005-07-15
CZ20011035A3 (cs) 2001-10-17
ES2214872T3 (es) 2004-09-16
CA2343299A1 (en) 2000-04-06
AU4975099A (en) 2000-04-17
ID30255A (id) 2001-11-15
CN1342072A (zh) 2002-03-27
AP2001002112A0 (en) 2001-06-30
NO20011615L (no) 2001-04-24
EP1117392B1 (en) 2004-02-25
PL346980A1 (en) 2002-03-11
SK4122001A3 (en) 2002-06-04
BR9914098A (pt) 2001-07-31
OA11787A (en) 2005-07-26
YU23901A (sh) 2003-07-07
SI1117392T1 (en) 2004-06-30
EP1117392A1 (en) 2001-07-25
CA2343299C (en) 2008-04-01
IS5889A (is) 2001-03-14
AP1708A (en) 2007-01-10
EE200100199A (et) 2002-06-17
AU768474B2 (en) 2003-12-11
DE69915084T2 (de) 2004-07-22
DK1117392T3 (da) 2004-06-14
DE69915084D1 (de) 2004-04-01
HUP0103648A2 (hu) 2003-08-28
PT1117392E (pt) 2004-07-30
IL141953A (en) 2006-07-05
HUP0103648A3 (en) 2003-10-28
ATE260100T1 (de) 2004-03-15
JP2002525321A (ja) 2002-08-13
IL141953A0 (en) 2002-03-10
WO2000018395A1 (en) 2000-04-06
NO20011615D0 (no) 2001-03-29
TR200100901T2 (tr) 2001-08-21
CN1197565C (zh) 2005-04-20
KR20010079955A (ko) 2001-08-22
US20080119561A1 (en) 2008-05-22
EA200100370A1 (ru) 2001-10-22
NZ510500A (en) 2003-10-31
ZA200102230B (en) 2002-06-18
EA007427B1 (ru) 2006-10-27
HRP20010236A2 (en) 2002-04-30
HK1042436A1 (en) 2002-08-16

Similar Documents

Publication Publication Date Title
ITTO950104A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
ITTO950099A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
ZA966798B (en) Methods of reducing or maintaining reduced levels of blood lipids using OB protein compositions.
IT1293690B1 (it) Stent per angioplastica, particolarmente per il trattamento di lesioni aorto-ostiali ed ostiali.
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
BR9811099A (pt) Inibidores de urocinase
BR9914044A (pt) ésteres tetrahidropirido
EE200100507A (et) Hüdroksümatairesinool vähkkasvaja vältimises
YU23901A (sh) Upotreba sredstva za snižavanje holesterola u sprečavanju i odlaganju revaskularizacije pomoću katetera
DK0998287T3 (da) Anvendelse af levobupivacain
WO2000071515A3 (en) INHIBITORS OF FACTOR Xa
NO944764D0 (no) Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
DE69935873D1 (de) 2-Methyl-thieno-benzodiazepin Formulierung
SE9603725D0 (sv) New teatment
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
NO973081D0 (no) Fremgangmåte for behandling av kroniske progressive vaskulære sykdommer
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
NO20005548D0 (no) Mykobakterieinhibitorer
EP0983376A4 (en) DETECTION METHODS FOR REAGENTS THAT REGULATE THE "INHIBITOR-THE-APOPTOSE-PROTEIN" (IAP) AND THAT AFFECT THE CASPASE ACTIVITY
GB9111580D0 (en) Nucleoside derivative